【摘要】 目的观察β受体阻滞剂美托洛尔对慢性心力衰竭(CHF)远期预后的影响。方法选择CHF患者65例,随机分为对照组(20例)和治疗组(45例)。对照组采用综合疗法。治疗组在上述基础上加用美托洛尔(6·25~12·5mg/d)。在治疗前和观察期满2年时分别对心功能NYHAⅡ~Ⅲ患者作踏车负荷试验,记录患者所能耐受的最大运动功率和运动持续时间。结果2年期间,对照组和治疗组因心力衰竭加重再住院率分别为82·76%和25·58%(P<0·005),病死率分别为31·03%和9·30%(P<0·025);与治疗前相比,治疗组心功能(NYHA分级)、最大运动功率和运动持续时间均明显改善(P<0·001),而对照组各项指标无明显改善。结论美托洛尔可显著改善CHF患者的远期预后。更多还原

【Abstract】 Objective To investigate the lo ng-term effect of motoprolol on the patients with chronic heart failure(CHF). Methods Sixty-five CHF patients were divided into the traetment group(45 cases) and the control group(20 cases) randomly.The general therapy was given to the control group.Besides this therapy,motoprolol(6.25～12.5mg) was ad ded to the treatment group.The pedal stress test was performed in the CHF patien ts with NYHA class Ⅱ～Ⅲ prior to and at the end of 2-year treatment.The maxim um motion quantity(Mqmax) and the motion continuance time(MCT) were recorded. Results The rehospitalization rate was 82.76% in the control group and 25.58% in the treatment group(P<0.005).The mortality rate was 31.03% in the control group and 9.30% in the treatment group(P <0.025) within 2 years.After 2 years,the heart function(NYHA),Mqmax and MCT i mproved obviously in the treatment group(P<0.001,respectively), but did not change significantly in the control group.Conclusion The long-term prognosis can be improved by perindopril in the CHF patients.更多还原